Kallisio

Kallisio is a private, commercial-stage medical device company pioneering personalized, oral-cavity-based solutions to enhance treatment accuracy and safety, primarily in oncology. Its core technology platform integrates patient anatomical data with intelligent design software and 3D printing to produce custom-fit medical devices, beginning with the Stentra™ system for head and neck radiation therapy. The company targets the significant clinical need to reduce side effects and improve workflow efficiency in precision oncology, leveraging a team with deep medtech experience and partnerships with leading cancer centers. Kallisio operates on a B2B model, providing devices and digital services to healthcare institutions, and is backed by established reimbursement pathways for its flagship product.

Integrated platform combining patient anatomical data, intelligent design automation software, and rapid 3D printing to create custom-fit, oral-cavity-based medical devices for precision treatment and drug delivery.

Kallisio competes in the niche of personalized 3D-printed medical devices for oncology. Direct competitors may include other startups or academic spin-offs developing custom immobilization devices. Indirectly, it competes against generic, off-the-shelf positioning aids and the status quo of manual setup. Its defensibility lies in its integrated software-to-manufacturing platform, clinical validation, and established reimbursement.